Abemaciclib with gemcitabine for soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of soft tissue sarcoma (either leiomyosarcoma, dedifferentiated liposarcoma, or another type if you are in the first part of the study).
- Your tumor must have a normal Rb gene (tested on a biopsy or archived sample).
- You must be able to swallow pills and have good kidney and liver function based on blood tests.
- You cannot have had gemcitabine before if you are in the second part of the study (for leiomyosarcoma or liposarcoma).
- You must be 18 or older, and if you could become pregnant, you must use effective birth control during and for a time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
This trial tests a combination of two drugs—cadonilimab (a type of immunotherapy) and adriamycin (chemotherapy)—for adults with advanced soft tissue sarcoma that hasn't been treated before. The goal is to see if this combination helps shrink tumors or slow their growth.
This trial tests a combination of two drugs—gemcitabine (a chemotherapy drug) and nab-sirolimus (a targeted therapy)—for people with advanced soft-tissue sarcoma or leiomyosarcoma, especially those whose tumors have a specific genetic change in the TSC2 or TSC1 genes. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests abemaciclib (a cancer medicine) in adults with advanced, unresectable bone or soft-tissue sarcoma that has certain gene changes in the “CDK pathway.” It aims to shrink tumors or slow growth in people whose tumors match the study’s biomarker and lab requirements.
This trial tests a chemotherapy combination (gemcitabine and docetaxel), given with or without bevacizumab (a drug that blocks blood vessel growth), for advanced soft tissue sarcomas that have been treated before. The goal is to see if adding bevacizumab helps slow cancer growth.
Hear when a new Advanced Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.